Nautilus Biotechnology (NAUT) Short-term Investments (2020 - 2026)

Nautilus Biotechnology has reported Short-term Investments for 7 years, with the latest figure at $70.9 million in Q2 2026.

• Quarterly Short-term Investments fell 37.52% year-over-year to $70.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $70.9 million (down 37.52% YoY) and the FY2025 annual result came in at $91.0 million, down 10.98% from the prior year.
• Short-term Investments retreated to $70.9 million in Q2 2026 per NAUT's latest filing, from $81.2 million in the prior quarter.
• Over five years, Short-term Investments peaked at $155.6 million in Q1 2024 and troughed at $69.0 million in Q3 2022.
• A 5-year average of $105.7 million and a median of $103.9 million in 2024 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2022 and 2023: Short-term Investments tumbled 56.31% in 2022, then soared 120.19% in 2023.
• Over 5 years, Short-term Investments stood at $69.9 million in 2022, then jumped by 120.19% to $154.0 million in 2023, then slumped by 33.61% to $102.2 million in 2024, then decreased by 10.98% to $91.0 million in 2025, then decreased by 22.14% to $70.9 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $70.9 million, $81.2 million, and $91.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.